Incyte up after blood cancer therapy meets main goal in late-stage trial

Incyte

05/01/2026 13:04

** Shares of drugmaker Incyte INCY.O up 2.3% at $103.73 premarket

** INCY says its experimental combo therapy met the main goal in a late-stage trial testing patients with a type of blood cancer

** The trial tested a combination of tafasitamab, lenalidomide and standard chemotherapy in which the therapy improved progression-free survival in patients newly diagnosed with diffuse large B-cell lymphoma

** Incyte plans to seek expanded approval in H1 2026

** In last 12 months, stock up 2.7% YTD

 (Reporting by Siddhi Mahatole)

 ((siddhi.mahatole@thomsonreuters.com))